Information updates

ASCIA Immunodeficiency Strategy launch

The ASCIA Immunodeficiency Strategy was launched on Friday 29 April 2022, 9-9.45am AEST, during World Primary Immunodeficiency (PID) Week 22-29 April 2022 and on the International Day of Immunology, 29 April 2022. 

ASCIA has worked in collaboration with patient organisations to develop the Strategy and the first goal is to enable early diagnosis of severe combined immune deficiency (SCID) by newborn screening (NBS) of the Australian population. 

Media coverage of the Strategy launch was extensive, and mainly focused on the need for routine SCID NBS. Links to open access media articles are shown below. 

Following the Strategy launch, in June 2022 the formal recommendation for SCID to be included in Australian Newborn Bloodspot Screening Programs was announced in a media statement by the Australian Government

The Queensland state government has announced that they will fund routine SCID NBS and the statement is available here:

It is anticipated that other Australian states will make funding commitments for SCID NBS following these announcements.

A media release for the Strategy launch is available here pdfASCIA IMMUNODEFICIENCY STRATEGY MEDIA RELEASE 2022-04-29226.29 KB or you can view it online at

A media release was also issued for HAE Day on 16 May 2022, and this is available at 

Links to open access media articles are available here:

This news item was issued on 29 April 2022 and updated on 1 July 2022 by Jill Smith, CEO of the Australasian Society of Clinical Immunology and Allergy (ASCIA). ASCIA is the peak professional body for clinical immunology and allergy in Australia and New Zealand.  

Mod ASCIA Member
Donate to AIFA
go to NAC website

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Information Partner

Official Information Partner of Healthdirect Australia